XSTO
PROGEN
Market cap1mUSD
Apr 30, Last price
1.88SEK
1D
6.21%
1Q
-78.39%
IPO
-73.89%
Name
Prostatype Genomics AB
Chart & Performance
P/E
—
P/S
63.34
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-36.00%
Rev. gr., 5y
21.85%
Revenues
199k
-85.32%
Net income
-41m
L-0.93%
CFO
-45m
L+53.44%
Profile
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | 199 -85.32% | 1,356 98.59% | 683 6,727.30% | ||||||
Cost of revenue | 492 | 22,671 | 42,778 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (293) | (21,315) | (42,095) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 1,676 | ||||||||
Tax Rate | |||||||||
NOPAT | (293) | (21,315) | (43,771) | ||||||
Net income | (41,051) -0.93% | (41,435) 42.45% | (29,087) 86.10% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 66,151 | 18,111 | |||||||
BB yield | -198.42% | -110.79% | |||||||
| Debt | |||||||||
Debt current | 11,600 | 400 | |||||||
Long-term debt | 67 | 467 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | (1,000) | 2 | |||||||
Net debt | (9,420) | 8,985 | (4,013) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (44,709) | (29,138) | (27,693) | ||||||
CAPEX | (285) | (75) | |||||||
Cash from investing activities | (8,356) | (8,566) | |||||||
Cash from financing activities | 59,751 | 28,911 | 18,853 | ||||||
FCF | 9,905 | (31,821) | (43,760) | ||||||
| Balance | |||||||||
Cash | 9,420 | 2,682 | 11,489 | ||||||
Long term investments | (6,609) | ||||||||
Excess cash | 9,410 | 2,614 | 4,845 | ||||||
Stockholders' equity | 670 | 7,168 | (123,167) | ||||||
Invested Capital | 32,799 | 33,726 | 149,945 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 3,003 | 172,069 | 88,444 | ||||||
Price | 11.10 11,584.21% | 0.10 -95.52% | 2.12 -76.29% | ||||||
Market cap | 33,339 103.95% | 16,347 -91.28% | 187,500 -69.60% | ||||||
EV | 23,919 | 25,332 | 183,488 | ||||||
EBITDA | (293) | (19,440) | (40,191) | ||||||
EV/EBITDA | |||||||||
Interest | 1,677 | 1,540 | 396 | ||||||
Interest/NOPBT | |||||||||